Greater access to life-extending drug for people with metastatic breast cancer

Greater access to life-extending drug for people with metastatic breast cancer

28 Aug 2024

For those living with the newly defined HER2-low subtype of metastatic breast cancer, this is a vital development that will extend their lives and improve quality of life.

Until now, the high cost of each treatment – $10,000 to $15,000 every three months – has kept it out of reach of most Australians. The Government’s milestone decision to list it on the PBS reduces that cost to just $31.60 ($7.70 concession) per treatment.

In clinical trials, Enhertu was shown to extend the time without the cancer progressing by an average of almost 10 months compared to the current standard treatment. Overall, it extended survival by more than 23 months.

We are extremely proud to have played a role in this achievement through working with government and amplifying the voice of our members.

This is a part of our commitment to secure better treatments, support, and policies to benefit those living with metastatic disease.

Categories

Popular Posts

Tags